Vol. 23/ No. 22

Benjamin P. Levy, MD; Bhuvana Ramkumar, MD; and Neil Morganstein, MD, discuss the challenges with tissue testing facing care teams, as well as multilevel hurdles in procurement, analysis of results, and insurance.

Patients with localized pancreatic adenocarcinoma who received care at a multidisciplinary clinic had significantly higher neoadjuvant therapy completion rates than those treated at a specialty-specific clinic.

Ensuring a positive patient experience should be a top priority throughout the entire treatment journey, as higher patient satisfaction can drive improved health outcomes, treatment adherence, and quality of life.

Molecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods are taken up in clinical practice.

A variety of factors must be considered for treatment decisions for patients with renal cell carcinoma due to the expanded number of options available to clinicians.

CAR T-cell therapies have generated considerable enthusiasm in the oncology community since the first FDA approval in 2017.

Early experience with a newly designed pancreatic cancer multidisciplinary clinic workflow at Roswell Park Comprehensive Cancer Center in Buffalo, New York, showed significant improvement in terms of time to subspecialty evaluation.

A core component of any type of therapeutic research is to enhance clinical benefit.